The research company Aptahem reports, as planned, no revenue during the fourth quarter. The operating loss decreased.The operating result was SEK -1.7 million (-2.7). The result after tax was SEK -1.7 million (-2.9). Cash and cash equivalents amounted to SEK 3 million (4.1)."The fourth quarter has been one of the most strategically significant quarters in Aptahem’s history. During the period we have taken several important steps to further clarify the company’s positioning as a focused clinical development company, deepen the clinical development plan for Apta-1, and strengthen the commercial appeal to potential partners and investors", says CEO Mikael Lindstam in the report. He also testifies to strong interest in the company and that they have very high activity in their data room."We are currently experiencing the largest and most continuous demand for company information in Aptahem’s history, from both industrial players and financial stakeholders", says Lindstam. "Business development has been a prioritized area during the quarter. We have deepened dialogues regardingpossible partnerships, including structures that may include clinical collaboration, licensing, and regional as well as global rights. In parallel, we have intensified our USA-related work and continue to explore opportunities to raise capital in the American market, without any formal steps having been taken yet", he continues. Aptahem, SEK millionQ4-2025Q4-2024ChangeNet sales00Operating result-1.7-2.7Net income-1.7-2.9Cash and cash equivalents34.1-26.8%